FDA Public Health Advisory Suspended Marketing of Palladone (hydromorphone hydrochloride, extended release capsules) | |
This product is not currently available for purchase in the U.S. FDA is issuing this public health advisory to inform patients and health care providers that the sponsor of Palladone, Purdue Pharma, has agreed to suspend sales and marketing of Palladone (hydromorphone hydrochloride, extended release capsules), a potent narcotic painkiller, because of the potential for severe side effects if Palladone is taken with alcohol. |
|
FDA is announcing the following, effective immediately:
Palladone is a time-release formulation of hydromorphone, a potent narcotic painkiller. Palladone is taken once-a-day and the capsule slowly releases a steady amount of hydromorphone into the body over that whole day. Palladone is approved for treatment of moderate to severe chronic pain only in opiate-tolerant patients (that is, patients who have been taking opiate containing products for a considerable period of time). Palladone has been sold in the U.S. only since January 2005 and has been used only by a small number of patients. To date, FDA is not aware of any patients who have had life-threatening side effects from drinking alcohol while taking Palladone. Date created: July 13, 2005, updated: July, 2007 |
|
© 2007 Directory of Drugs - reference guide to drugs - All rights reserved - Legal Notice